Cmc Biologics
COPENHAGEN, Denmark and SEATTLE, November 9, 2011 -
Single-use technologies are widely accepted in the biomanufacturing of biological therapeutics and vaccines.
SEATTLE and COPENHAGEN, Denmark, October 26, 2011 -
CMC Biologics today announced the execution of an agreement with Daiichi Sankyo Co., Ltd.
SEATTLE, COPENHAGEN, Denmark and LAGUNA NIGUEL, California, September 20, 2011 -
CMC Biologics and Inspiration Biopharmaceuticals ("Inspiration") today announced that the two companies have entered into a long-term commercial supply agreement for the manufacture of bulk IB1001, Inspiration's intravenous recombinant factor IX (rFIX) product, for the treatment and prevention of bleeding in individuals with hemophilia B.
SEATTLE, COPENHAGEN, Denmark and OXFORD, England, September 7, 2011 -
CMC Biologics and Oxford BioTherapeutics (OBT) today announced that they have entered into a non-exclusive license agreement providing OBT with access to CMC Biologics' CHEF1 expression system.
COPENHAGEN, Denmark and SEATTLE, September 1, 2011 -
- Several planned events highlight CMC Biologics' expertise in single-use technology
CMC Biologics today announced the completion of the installation of a 2,000 liter single-use bioreactor (2,000L SUB) at its manufacturing facility in Copenhagen.
